ASX - By Stock
|
MSB Biotech |
Re:
MSB - a new dawn
|
|
JDBL
|
2.4K |
1.0M |
4 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
2.4K
|
1.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
JDBL
|
444 |
193K |
2 |
27/07/25 |
27/07/25 |
ASX - By Stock
|
444
|
193K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
JDBL
|
19K |
8.4M |
1 |
26/07/25 |
26/07/25 |
ASX - By Stock
|
19K
|
8.4M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
JDBL
|
444 |
193K |
8 |
26/07/25 |
26/07/25 |
ASX - By Stock
|
444
|
193K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
JDBL
|
19K |
8.4M |
1 |
25/07/25 |
25/07/25 |
ASX - By Stock
|
19K
|
8.4M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ceasing to be a substantial holder
|
|
JDBL
|
10 |
4.6K |
1 |
25/07/25 |
25/07/25 |
ASX - By Stock
|
10
|
4.6K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Quarter 2 Ryoncil revenue projections
|
|
JDBL
|
210 |
93K |
7 |
24/07/25 |
24/07/25 |
ASX - By Stock
|
210
|
93K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Dividend reinvestment plan for Neu
|
|
JDBL
|
35 |
14K |
3 |
22/07/25 |
22/07/25 |
ASX - By Stock
|
35
|
14K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
JDBL
|
16K |
8.1M |
9 |
21/07/25 |
21/07/25 |
ASX - By Stock
|
16K
|
8.1M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Chart
|
|
JDBL
|
429 |
185K |
6 |
18/07/25 |
18/07/25 |
ASX - By Stock
|
429
|
185K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
JDBL
|
16K |
8.1M |
16 |
18/07/25 |
18/07/25 |
ASX - By Stock
|
16K
|
8.1M
|
16
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - a new dawn
|
|
JDBL
|
2.4K |
1.0M |
5 |
18/07/25 |
18/07/25 |
ASX - By Stock
|
2.4K
|
1.0M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
JDBL
|
16K |
8.1M |
7 |
18/07/25 |
18/07/25 |
ASX - By Stock
|
16K
|
8.1M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
JDBL
|
18K |
6.6M |
4 |
17/07/25 |
17/07/25 |
ASX - By Stock
|
18K
|
6.6M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
JDBL
|
18K |
6.6M |
6 |
15/07/25 |
15/07/25 |
ASX - By Stock
|
18K
|
6.6M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
JDBL
|
18K |
6.6M |
7 |
08/07/25 |
08/07/25 |
ASX - By Stock
|
18K
|
6.6M
|
7
|
|
ASX - By Stock
|
NEU |
Re:
M&A
|
|
JDBL
|
249 |
138K |
28 |
05/07/25 |
05/07/25 |
ASX - By Stock
|
249
|
138K
|
28
|
|
ASX - By Stock
|
NEU |
Re:
M&A
|
|
JDBL
|
249 |
138K |
26 |
04/07/25 |
04/07/25 |
ASX - By Stock
|
249
|
138K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
JDBL
|
18K |
6.6M |
0 |
03/07/25 |
03/07/25 |
ASX - By Stock
|
18K
|
6.6M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast and FDA Align on Key Items for Revascor BLA
|
|
JDBL
|
129 |
71K |
3 |
02/07/25 |
02/07/25 |
ASX - By Stock
|
129
|
71K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast and FDA Align on Key Items for Revascor BLA
|
|
JDBL
|
129 |
71K |
4 |
02/07/25 |
02/07/25 |
ASX - By Stock
|
129
|
71K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast and FDA Align on Key Items for Revascor BLA
|
|
JDBL
|
129 |
71K |
2 |
02/07/25 |
02/07/25 |
ASX - By Stock
|
129
|
71K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast and FDA Align on Key Items for Revascor BLA
|
|
JDBL
|
129 |
71K |
11 |
02/07/25 |
02/07/25 |
ASX - By Stock
|
129
|
71K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
MSB Broker Data
|
|
JDBL
|
136 |
66K |
0 |
01/07/25 |
01/07/25 |
ASX - By Stock
|
136
|
66K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB Broker Data
|
|
JDBL
|
136 |
66K |
8 |
01/07/25 |
01/07/25 |
ASX - By Stock
|
136
|
66K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
JDBL
|
16K |
8.1M |
0 |
26/06/25 |
26/06/25 |
ASX - By Stock
|
16K
|
8.1M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
JDBL
|
1.6K |
830K |
1 |
26/06/25 |
26/06/25 |
ASX - By Stock
|
1.6K
|
830K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Shorts
|
|
JDBL
|
358 |
121K |
0 |
25/06/25 |
25/06/25 |
ASX - By Stock
|
358
|
121K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Becoming a substantial holder
|
|
JDBL
|
76 |
31K |
7 |
06/06/25 |
06/06/25 |
ASX - By Stock
|
76
|
31K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
JDBL
|
1.8K |
1.0M |
0 |
05/06/25 |
05/06/25 |
ASX - By Stock
|
1.8K
|
1.0M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - a new dawn
|
|
JDBL
|
2.4K |
1.0M |
4 |
04/06/25 |
04/06/25 |
ASX - By Stock
|
2.4K
|
1.0M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - a new dawn
|
|
JDBL
|
2.4K |
1.0M |
8 |
02/06/25 |
02/06/25 |
ASX - By Stock
|
2.4K
|
1.0M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Becoming a substantial holder
|
|
JDBL
|
92 |
49K |
0 |
27/05/25 |
27/05/25 |
ASX - By Stock
|
92
|
49K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval
|
|
JDBL
|
272 |
111K |
2 |
19/05/25 |
19/05/25 |
ASX - By Stock
|
272
|
111K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval
|
|
JDBL
|
272 |
111K |
15 |
19/05/25 |
19/05/25 |
ASX - By Stock
|
272
|
111K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ryoncil Is Now Available For Purchase In The United States
|
|
JDBL
|
266 |
96K |
4 |
17/05/25 |
17/05/25 |
ASX - By Stock
|
266
|
96K
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - a new dawn
|
|
JDBL
|
2.4K |
1.0M |
4 |
15/05/25 |
15/05/25 |
ASX - By Stock
|
2.4K
|
1.0M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - a new dawn
|
|
JDBL
|
2.4K |
1.0M |
0 |
14/05/25 |
14/05/25 |
ASX - By Stock
|
2.4K
|
1.0M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - a new dawn
|
|
JDBL
|
2.4K |
1.0M |
5 |
14/05/25 |
14/05/25 |
ASX - By Stock
|
2.4K
|
1.0M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast 2025: The year of acting like a publicly listed company
|
|
JDBL
|
1.4K |
549K |
3 |
06/05/25 |
06/05/25 |
ASX - By Stock
|
1.4K
|
549K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Becoming a substantial holder
|
|
JDBL
|
29 |
13K |
8 |
06/05/25 |
06/05/25 |
ASX - By Stock
|
29
|
13K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
JDBL
|
19K |
8.4M |
2 |
05/05/25 |
05/05/25 |
ASX - By Stock
|
19K
|
8.4M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - a new dawn
|
|
JDBL
|
2.4K |
1.0M |
0 |
01/05/25 |
01/05/25 |
ASX - By Stock
|
2.4K
|
1.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Director Appointment
|
|
JDBL
|
58 |
22K |
18 |
29/04/25 |
29/04/25 |
ASX - By Stock
|
58
|
22K
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
JDBL
|
1.8K |
1.0M |
16 |
24/04/25 |
24/04/25 |
ASX - By Stock
|
1.8K
|
1.0M
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Phase out of Red dye
|
|
JDBL
|
4 |
2.1K |
12 |
24/04/25 |
24/04/25 |
ASX - By Stock
|
4
|
2.1K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
JDBL
|
6.9K |
3.6M |
4 |
22/04/25 |
22/04/25 |
ASX - By Stock
|
6.9K
|
3.6M
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Update - Notification of buy-back - NEU
|
|
JDBL
|
79 |
36K |
5 |
16/04/25 |
16/04/25 |
ASX - By Stock
|
79
|
36K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: NEU confirms primary endpoints for Phase 3 trial in PMS
|
|
JDBL
|
160 |
83K |
3 |
15/04/25 |
15/04/25 |
ASX - By Stock
|
160
|
83K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Meeting Requested with FDA on Revascor Accelerated Approval
|
|
JDBL
|
129 |
56K |
0 |
03/04/25 |
03/04/25 |
ASX - By Stock
|
129
|
56K
|
0
|
|